SPONSORED CONTENT: Scaling programs from clinical trials to commercialization requires more than raw capacity — it demands supply chain redundancy and rigid quality systems, notes Kerrie Powell from Alcami.

The simultaneous adoption of eCTD v4.0 and GxP-compliant AI tools offers the biopharma industry potentially tremendous efficiency gains; however, success will ultimately depend upon organizational agility.

The company has managed to raise USD 70 million, which it will use to progress its lead candidate into first-in-human clinical trials and broaden its pipeline of siRNA medicines.

Long-term value creation in bio/pharma now hinges on embedding environmental targets into early-phase development, according to Russell Miller from Enzene.

Through this acquisition, Eli Lilly will strengthen its immunology capabilities by gaining access to a first-in-class antibody-degradation platform that has been designed to remove disease-causing antibodies.

Scaling point-of-care and modular manufacturing requires companies to move beyond traditional paper-based reviews and into real-time digital execution with embedded quality control.

The new Sepion 75 supports flexible batch processing, closed material handling, and direct transfer of process parameters from pilot to commercial production.

Through this certified status, the CDMO will be able to offer its customers targeted, multiplex protein biomarker analysis alongside its human-relevant disease models.

Once limited by poor bioavailability and enzymatic degradation, oral peptides are now on the cusp of becoming the next blockbuster class, reveal Hong Li and Lixia Zhang from BioDuro.

Although the trial did not meet its primary endpoint, EyePoint reported a 42% reduction in overall treatment burden, with most patients requiring zero or one supplemental injection through Week 56.

The shift from high-volume drugs to niche biologics requires a more than just expanded footprints, it demands smarter bioprocess controls, lower COGs early on in development, and cross-functional teams.

The money from the oversubscribed Series C round will fund pivotal development of EPI‑321, a clinical-stage epigenetic therapy for FSHD, and supports late-stage development and expansion of manufacturing and pipeline programs.

The funds will be used to advance two complementary eczema programs that leverage millions of screened human memory B cells and protein language models to deliver more potent and longer‑acting antibodies.

Driven by the rise of primary-care biologics and value-based healthcare, oral peptides and proteins are challenging traditional injectable paradigms, reveals Giuseppe De Franza from Adare Pharma Solutions.

The new partnership model combines Enzene’s continuous manufacturing platform with facility design, technology transfer, and operational support to help regions build cost-efficient biologics production capacity.

As the divide between upstream output and downstream capability in bioprocessing expands, it is becoming necessary for the biopharma industry to address plant capacity, process intensification, digital connectivity, and business feasibility.

By combining Nottingham’s development capabilities with its expanded Haverhill site, Codis creates an integrated UK pathway spanning early-stage development to commercial-scale supply.

The first UK patient has been dosed in the Phase I NEOVACC trial using Touchlight’s proprietary doggybone DNA technology to manufacture a bespoke cancer vaccine.

After closing an all-stock merger with complement specialist Kira Pharmaceuticals, Jasper Therapeutics is set to create a diversified immunology company.

The companies have entered into a research collaboration to optimize secretion of therapeutic proteins targeting improved durability and efficiency of adeno-associated virus (AAV)-delivered gene medicines.